Affordable Access

deepdyve-link
Publisher Website

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.

Authors
  • Wolchok, J D1
  • Weber, J S
  • Maio, M
  • Neyns, B
  • Harmankaya, K
  • Chin, K
  • Cykowski, L
  • de Pril, V
  • Humphrey, R
  • Lebbé, C
  • 1 Ludwig Institute of Cancer Research, Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. [email protected]
Type
Published Article
Journal
Annals of Oncology
Publisher
Oxford University Press
Publication Date
Aug 01, 2013
Volume
24
Issue
8
Pages
2174–2180
Identifiers
DOI: 10.1093/annonc/mdt161
PMID: 23666915
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

This analysis was carried out to evaluate the long-term survival of patients with metastatic melanoma who received ipilimumab, a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte antigen-4, in clinical trials. Patients received ipilimumab in one of three completed phase II clinical trials (CA184-008, CA184-022, and CA184-007). Previously treated patients were enrolled in all studies, and treatment-naïve patients were also included in study CA184-007. Patients received ipilimumab at a dose of 10 mg/kg in studies CA184-008 and CA184-007, and at doses of 0.3, 3, or 10 mg/kg in study CA184-022. Ipilimumab was given every 3 weeks for four doses, and eligible patients could receive ipilimumab maintenance therapy every 12 weeks. In study CA184-022, patients could cross over to be retreated with ipilimumab at 10 mg/kg upon disease progression. Ongoing survival follow-up is conducted in a companion study, CA184-025. Four-year survival rates [95% confidence interval (95% CI)] for previously treated patients who received ipilimumab at 0.3, 3, or 10 mg/kg were 13.8% [6.1-22.5], 18.2% [9.5-27.6], and 19.7% [13.4-26.5] to 28.4% [13.9-44.2], respectively. In treatment-naïve patients who received ipilimumab at 10 mg/kg, 4-year survival rates were 37.7% [18.6-57.4] to 49.5% [23.8-75.4]. These results demonstrate durable survival in a significant proportion of patients with metastatic melanoma who received ipilimumab therapy.

Report this publication

Statistics

Seen <100 times